ReviewDiagnostics (Basel, Switzerland)2026
Recent Advances in Multimodal Assessment Scoring Systems for Prostate Cancer: An Integrated Pathological and Imaging Perspective.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In the clinical management of prostate cancer, continuously refined scoring systems form the cornerstone of precise risk stratification. Pathological assessment systems, represented by the Gleason score and the International Society of Urological Pathology (ISUP) grade groups, have long been the cornerstone of prostate cancer risk stratification; however, they are subject to inherent limitations such as sampling bias and spatial heterogeneity. With advances in imaging technology, the PI-RADS scoring system based on multiparametric magnetic resonance imaging (mpMRI) has been widely adopted for the detection and localization of prostate cancer; however, inter-observer variability remains a significant issue in clinical practice. Concurrently, emerging functional imaging scoring systems based on PSMA-PET, such as PSMA-RADS and miTNM staging, have provided new tools for the precise staging of prostate cancer and restaging following biochemical recurrence. Currently, an increasing number of studies are attempting to integrate pathological and multimodal imaging information to construct comprehensive predictive models, thereby addressing the shortcomings of single-modality assessment methods, achieving more personalized and precise risk stratification, and ultimately optimizing treatment decisions and improving patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.